Conference Papers
Dore GJ; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Conway B; Nahass R; Luetkemeyer A; Peng C-Y; Iser DM; Gendrano IN; Kelly MM; Huang H-C; Hwang P; Barr E; Robertson M; Platt H, 2017, 'Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B', in HEPATOLOGY, WILEY, DC, Washington, pp. 112A - 113A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089800196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Lamoury F; Hajarizadeh B; Mowat Y; Marshall A; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore G; Applegate TL, 2017, 'Field evaluation of Xpert (R) HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S709 - S709, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31900-1
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; Mchutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S274 - S274, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30862-0
Cunningham EB; Hajarizadeh B; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Dore GJ; Lloyd AR; Grebely J, 2017, 'Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S488 - S488, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31370-3
Grebley J; Puoti M; Wedemeyer H; Cooper C; Sulkowski MS; Foster G; Berg T; Villa E; Rodriguez-Perez F; Wyles DL; Alami NN; Zhang Z; Dumas E; Dore GJ, 2017, 'Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S514 - S514, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31430-7
Lubel JS; Pianko S; Thompson A; Strasser S; Dore G; Stuart K; MacQuillan G; Iser D; Mitchell J; Gazzola A; Chivers S; Mishra G; Gow P; George J; Gough J; Tse E; Zekry A; Levy M; Fragomeli V; Morales B; Sasadeusz J; Nazareth S; Bollipo S; Jones T; Wade A; Cheng W; Wigg A; Roberts S, 2017, 'Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir plus /- ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis -Final results of the REV1TAL study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S521 - S521, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31444-7
Foster GR; Thompson AJ; Ruane PJ; Borgia SM; Dore G; Workowski K; Hyland RH; Wang J; Svarovskaia ES; Stamm LM; Brainard DM; Subramanian M; McHutchison JG; Berg T; Agarwal K; Conway B; Feld JJ; Willems BE; Roberts SK, 2016, 'A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study', in HEPATOLOGY, WILEY, MA, Boston, pp. 135A - 136A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493800259&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lubel J; Mitchell J; Pianko S; Thompson AJ; Iser DM; Gazzola A; Chivers S; Mishra G; Gough J; Strasser SI; Dore G; Stuart KA; George J; Tse E; Zekry A; Levy M; MacQuillan GC; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo SJ; Jones TL; Wade AJ; Roberts SK, 2016, 'Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV Genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL Study', in HEPATOLOGY, WILEY, MA, Boston, pp. 483A - 484A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802224&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lubel J; Mitchell J; Pianko S; Thompson AJ; Iser DM; Gazzola A; Chivers S; Mishra G; Gough J; Strasser SI; Dore G; Stuart KA; George J; Tse E; Zekry A; Levy M; MacQuillan GC; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo SJ; Jones TL; Wade AJ; Roberts SK, 2016, 'Frequency and severity of biochemical abnormalities with paritaprevir/ritonavir/ombitasvir +/- ribavirin in a real-world cohort of HCV Genotype 1 patients - predictors and clinical significance', in HEPATOLOGY, WILEY, MA, Boston, pp. 442A - 442A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802154&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lamoury F; Hajarizadeh B; Martinello M; Soker A; Martinez D; Cunningham P; Cloherty GA; Marks P; Matthews G; Amin J; Grebely J; Dore G; Applegate TL, 2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, MA, Boston, pp. 415A - 415A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Grebely J; Byrne M; Marks P; Butler T; Amin J; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore G, 2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, MA, Boston, pp. 385A - 386A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016
Dore GJ; Altice F; Litwin AH; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Gendrano IN; Huang HC; Chen E; Nguyen BY; Wahl J; Barr E; Robertson R; Platt HL, 2016, 'C-EDGE CO-STAR: Risk of reinfection following successful therapy with elbasvir and grazoprevir in persons who inject drugs (PWID) receiving opioid agonist therapy (OAT)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 70 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lubel J; Mitchell J; Pianko S; Thompson A; Iser D; Gazzola A; Chivers S; Mishra G; Gough J; Strasser S; Dore G; Stuart K; George J; Tse E; Zekry A; Levy M; Macquillan G; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo S; Jones T; Wade A; Roberts SK, 2016, 'Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 77 - 78, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lubel J; Mitchell J; Pianko S; Thompson A; Iser D; Gazzola A; Chivers S; Mishra G; Gough J; Strasser S; Dore G; Stuart K; George J; Tse E; Zekry A; Levy M; Macquillan G; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo S; Jones T; Wade A; Roberts SK, 2016, 'Frequency and severity of hyperbilirubinaemia with Viekira Pak in a real-world cohort of HCV genotype 1 patients - Predictors and clinical significance', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 78 - 79, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700140&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore GJ, 2016, 'INTERFERON-FREE HCV THERAPY FOR PEOPLE WHO INJECT DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 15 - 15, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398381500038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Arduino JM; Shibolet O; Litwin AH; Grebeley J; Altice F; Nwankwo C; Mast TC; Jiang Z; Gendrano IN; Platt HL; Dore GJ, 2016, 'C-EDGE CO-STAR: FAVORABLE IMPACT OF ELBASVIR AND GRAZOPREVIR ON HEALTH-RELATED QUALITY OF LIFE IN TREATMENT-NAIVE HCV-INFECTED PERSONS WHO INJECT DRUGS RECEIVING OPIOID AGONIST THERAPY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S403 - S404, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00638-3
Dore G; Altice F; Litwin AH; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Gendrano IN; Huang H-C; Chen E; Nguyen B-Y; Wahl J; Barr E; Robertson M; Platt HL, 2016, 'C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR AND GRAZOPREVIR IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOID AGONIST THERAPY (OAT)', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S771 - S771, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01503-8
Martin NK; Vickerman P; Dore GJ; Grebely J; Miners A; Cairns J; Foster GR; Hutchinson SJ; Goldberg DJ; Martin TCS; Ramsay M; Hickman M, 2016, 'COMPARING INDIVIDUAL AND POPULATION PREVENTION BENEFITS OF EARLY DIRECT-ACTING ANTIVIRAL TREATMENT FOR HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S464 - S464, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00779-0
Hezode C; Dore G; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'DACLATASVIR PLUS SOFOSBUVIR PLUS RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT-EXPERIENCED PATIENTS WITH HCV GENOTYPE 3 INFECTION AND ADVANCED FIBROSIS OR CIRRHOSIS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S753 - S754, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000399133800054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Flamm S; Zeuzem S; Hyland R; Chang P; Ding X; Yun C; Brainard D; McHutchison J; Forns X; Mangia A; Dore G, 2016, 'ON-TREATMENT ILLICIT DRUG USE DID NOT IMPACT TREATMENT OUTCOME DURING THERAPY WITH LEDIPASVIR-SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN THE PHASE 3 ION-1 STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S776 - S777, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000399133800099&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Liu L; Ding X; McNally J; Osinusi A; Brainard D; Subramanian M; Sulkowski M; Feld J, 2016, 'SOF/VEL FOR 12 WEEKS IS WELL TOLERATED AND RESULTS IN HIGH SVR12 RATES IN PEOPLE RECEIVING OPIOID SUBSTITUTION THERAPY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S776 - S776, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000399133800098&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Cunningham EB; Luciani F; Hajarizadeh B; Betz-Stablein B; Bretana NA; Teutsch S; Dore GJ; Grebely J; Lloyd AR, 2016, 'STABLE INCIDENCE OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING, 2005-2014: THE HITS-P STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S614 - S614, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01138-7
Leroy V; Angus PW; Bronowicki J-P; Dore G; Hezode C; Pianko S; Pol S; Stuart KA; Tse E; McPhee F; Bhore R; Exposito MJJ; Thompson AJ, 2015, 'All-Oral Treatment With Daclatasvir (DCV) Plus Sofosbuvir (SOF) Plus Ribavirin (RBV) for 12 or 16 Weeks in HCV Genotype (GT) 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+Phase 3 Study', in HEPATOLOGY, WILEY-BLACKWELL, pp. 1380A - 1381A, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000367013200004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore G; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Grebely J; Howe AY; Nguyen B-YT; Wahl J; Barr E; Robertson M; Platt HL, 2015, 'C-EDGE CO-STAR: Efficacy of Grazoprevir and Elbasvir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 227A - 228A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375400041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Waziry RK; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G; Law M, 2015, 'Trends in end-stage liver disease among people notified with HBV or HCV in New South Wales, Australia: 2000-2014', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1121A - 1121A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015
Dore GJ; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw DR; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir plus Ribavirin or Telaprevir plus Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. S1084 - S1085, presented at 46th Annual Digestive Disease Week (DDW), DC, Washington, 16 May 2015 - 19 May 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000360120800122&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Jacobson IM; Dore GJ; Wyles D; Lawitz E; Talal A; Ball G; Dumas EO; Feld JJ, 2015, 'Plasma Interferon-gamma-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. S1087 - S1088, presented at 46th Annual Digestive Disease Week (DDW), DC, Washington, 16 May 2015 - 19 May 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000360120800131&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore G; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw D; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'P0847 : Malachite-II: Phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir + ribavirin or telaprevir + peginterferon/ribavirin in peginterferon/ribavirin treatment-experienced adults with HCV genotype 1', in Journal of Hepatology, Elsevier, AUSTRIA, Vienna, pp. s656 - s657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/s0168-8278(15)31049-7
Hickman M; Martin N; Vickerman P; David G; Hutchinson S; Martin T; Dore G; Grebeley J; Miners A; Foster G, 2015, 'P1271 : How should scale up of HCV antiviral treatment be prioritized? A cost-effectiveness analysis including individual and population prevention benefits', in Journal of Hepatology, Elsevier, AUSTRIA, Vienna, pp. s835, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/s0168-8278(15)31466-5
Hajarizadeh B; Grady B; Page K; Kim AY; Mcgovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J, 2014, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 study', in Journal of Viral Hepatitis, Blackwell Publishing Ltd, MA, Boston, pp. 708 - 717, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.1111/jvh.12384
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2014, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 425 - 434, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.3851/IMP3035
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2014, 'The impact of ribavirin plasma concentration on the eficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 127 - 132, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.3851/IMP2984
Doyle JS; Dore GJ; Shaw D; Grebely J; Erratt A; Hellard M; Matthews G, 2014, 'HCV re-infection rates are low after long-term follow up of acute HCV infection: The Australian Trial of Acute Hepatitis C Recall study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 915A - 915A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Sheridan DA; Hajarizadeh B; Matthews G; Applegate TL; Douglas MW; Askew B; Neely D; Bassendine MF; Dore GJ; Lloyd AR; George J; Grebely J, 2014, 'Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 929A - 929A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014
Jacka B; Poon A; Applegate TL; Krajden M; Olmstead A; Harrigan R; Marshall BD; DeBeck K; Milloy M-J; Lamoury F; Pybus O; Lima V; Magiorkinis G; Montoya V; Montaner J; Joy J; Dore GJ; Kerr T; Wood E; Grebely J, 2014, 'Hepatitis C virus network dynamics among people who inject drugs in Vancouver, Canada', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 907A - 908A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Reddy KR; Roberts SK, 2014, 'High Efficacy of Treatment with Sofosbuvir+GS-5816 +/- Ribavirin for 12 Weeks in Treatment Experienced Patients with Genotype 1 or 3 HCV Infection', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 297A - 298A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483801131&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Morris MD; Rice TM; Shiboski S; Bruneau J; Cox A; Dore GJ; Grebely J; Hahn JA; Kim AY; Lloyd AR; Hellard M; Maher L; McGovern BH; Prins M; Page K, 2014, 'Historical and geographical trends in hepatitis C virus (HCV) incident infection among people who inject drugs: The International Collaboration on Incident HCV and HIV Infection among PWID (InC3 Study)', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 894A - 895A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014
Hajarizadeh B; Grady BP; Page K; Kim AY; McGovern BH; Cox A; Rice TM; Sacks-Davis R; Bruneau J; Morris MD; Amin J; Schinkel J; Applegate TL; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ; Grebely J, 2014, 'Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 898A - 899A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014
Alavi M; Law M; Grebely J; Thein H-H; Amin J; Dore GJ; Law M, 2014, 'Time to hepatocellular carcinoma after notification of hepatitis B or C infection: a population-based cohort study, 1992-2007', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 921A - 922A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014
Martin NK; Vickerman P; Dore GJ; Grebely J; Foster GR; Miners A; Hutchinson S; Goldberg DJ; Martin TC, 2014, 'Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 1042A - 1042A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804314&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Foster GR; Jacobson IM; Dore GJ; Fried M; Manns M; Marcellin P; Poordad F; de Araujo ESA; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M, 2014, 'P1127 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN TREATMENT-NAIVE EUROPEAN PATIENTS IN THE QUEST-1 AND QUEST-2 PHASE III TRIALS', in Journal of Hepatology, Elsevier, ENGLAND, London, pp. s456, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014, http://dx.doi.org/10.1016/s0168-8278(14)61287-3
Martin NK; Devine A; Eaton JW; Hallett TB; Foster GR; Dore GJ; Easterbrook PJ; Legood R; Vickerman P, 2014, 'P1190 MODELING THE IMPACT OF EARLY ANTIRETROVIRAL THERAPY FOR ADULTS COINFECTED WITH HIV AND HEPATITIS B OR C IN SOUTH AFRICA', in Journal of Hepatology, Elsevier, ENGLAND, London, pp. s483, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014, http://dx.doi.org/10.1016/s0168-8278(14)61350-7
Dore GJ; Razavi H; Estes C; Thompson A; Zekry A; Roberts S; Sievert W, 2014, 'P427 POTENTIAL IMPACT OF IMPROVED TREATMENT ON DISEASE BURDEN OF CHRONIC HEPATITIS C IN AUSTRALIA', in Journal of Hepatology, Elsevier, ENGLAND, London, pp. s210, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014, http://dx.doi.org/10.1016/s0168-8278(14)60589-4
Jacka B; Applegate T; Poon AF; Harrigan R; Dore GJ; Olmstead A; DeBeck K; Milloy M-J; Lamoury F; Woods C; Brumme Z; Dobrer S; Lima VD; Montaner J; Joy J; Marshall BD; Kerr T; Wood E; Krajden M; Grebely J, 2014, 'P762 TEMPORAL CHANGES IN HEPATITIS C VIRUS GENOTYPE 3A DISTRIBUTION AMONG PEOPLE WHO INJECT DRUGS IN VANCOUVER, CANADA', in Journal of Hepatology, Elsevier, ENGLAND, London, pp. s324 - s325, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014, http://dx.doi.org/10.1016/s0168-8278(14)60923-5
Bradshaw D; Jacka B; Sacks-Davis R; Lamoury F; Applegate T; Dore G; Down I; Luciani F; Hellard M; Sasadeusz J; Danta M; Matthews G, 2014, 'A novel method comparing sexual networks with the HCV phylogeny in HIV-positive MSM with acute HCV infection identifies two potential intervention targets for permucosally transmitted HCV in Australia', in HIV MEDICINE, WILEY-BLACKWELL, pp. 136 - 136
Bradshaw D; Jacka B; Sacks-Davis R; Lamoury F; Applegate TL; Dore GJ; Down I; Luciani F; Hellard M; Sasadeusz J; Danta M; Matthews G, 2013, 'A novel method comparing sexual networks with the HCV phylogeny in HIV-positive men who have sex with men (MSM) with acute HCV infection identifies two potential intervention targets for permucosally-transmitted HCV', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 1307A - 1307A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013
Danta M; How-Chow D; McInnes E; Matthews G; Dore GJ, 2013, 'Growing burden of HCV-related advanced liver disease related to enhanced Fibroscan-based screening', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 956A - 957A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330252204331&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Page K; McGovern BH; Grebely J; Kim AY; Evans J; Morris MD; Cox A; Rice TM; Sacks-Davis R; Hellard M; Bruneau J; Shoukry N; Maher L; Lloyd AR; Prins M; Dore GJ, 2013, 'IL28B Genotype is Associated with Jaundice and Elevated Aminotransferase Levels During Acute HCV Infection', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 1188A - 1188A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013
Bradshaw D; Lamoury F; Catlett B; Applegate TL; Mcallister J; Dore GJ; Matthews G; Danta M, 2013, 'Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-positive men with acute HCV infection', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 913A - 913A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013
Jacobson IM; Dore GJ; Foster GR; Fried MW; Manns MP; Marcellin P; Poordad F; Araujo ES; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M, 2013, 'Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 756A - 757A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013
Back to profile page
https://orcid.org/0000-0002-4741-2622